Bill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, St. Leonards, New South Wales, Australia.
Australian Proteome Analysis Facility (APAF), Macquarie University, Sydney, Australia; Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, Australia.
Semin Cell Dev Biol. 2014 Mar;27:118-27. doi: 10.1016/j.semcdb.2014.04.002. Epub 2014 Apr 6.
Given the large socio-economic burden of cancer, there is an urgent need for in vivo animal cancer models that can provide a rationale for personalised therapeutic regimens that are translatable to the clinic. Recent developments in establishing mouse models that closely resemble human lung cancers involve the application of genetically engineered mouse models (GEMMs) for use in drug efficacy studies or to guide patient therapy. Here, we review recent applications of GEMMs in non-small cell lung cancer research for drug development and their potential in aiding biomarker discovery and understanding of biological mechanisms behind clinical outcomes and drug interactions.
鉴于癌症带来的巨大社会经济负担，迫切需要能够为可转化为临床实践的个体化治疗方案提供依据的体内动物癌症模型。最近，在建立与人肺癌非常相似的小鼠模型方面的进展涉及应用基因工程小鼠模型（GEMMs）进行药物疗效研究或指导患者治疗。在这里，我们综述了 GEMMs 在非小细胞肺癌药物开发研究中的最新应用，及其在辅助生物标志物发现和理解临床结果和药物相互作用背后的生物学机制方面的潜力。
